Ranked by reported Q4 2025 13F market value
Share of total reported institutional value in BCTXW held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 67K | $4K | β | 6.191% | 0.00% |
| 2 | Redmond Asset Management, LLC | 75K | $2K | 0.0% | 6.919% | 0.00% |
| 3 | L1 Global Manager Pty Ltd | 7K | $370 | β | 0.646% | 0.00% |
| 4 | Newbridge Financial Services Group, Inc. | 1K | $53 | 0.0% | 0.092% | 0.00% |
| 5 | HRT FINANCIAL LP | 21K | $1 | β | 1.923% | 0.00% |
| 6 | Virtu Financial LLC | 26K | $1 | β | 2.426% | 0.00% |
| 7 | ROYAL BANK OF CANADA | 225 | $0 | β | 0.021% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in BCTXW β a direct measure of their conviction.
Filings activity in BCTXW during Q4 2025, grouped by how each filer changed its position.
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q4 2025 | 7 | +133% | 199.99% | +0.00 pp | $0M | +113% |
| Q3 2025 | 3 | 63% | 199.99% | +0.00 pp | $0M | 75% |
| Q2 2025 | 8 | +0.0% | 199.99% | +0.00 pp | $0M | 22% |
| Q1 2025 | 8 | +100% | 199.99% | +0.00 pp | $0M | 86% |
| Q4 2024 | 4 | 20% | 199.99% | +0.00 pp | $0M | 44% |
| Q3 2024 | 5 | +0.0% | 199.99% | +0.00 pp | $0M | +63% |
| Q2 2024 | 5 | +25% | 199.99% | +0.00 pp | $0M | 80% |
| Q1 2024 | 4 | β | 199.99% | β | $1M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying BCTXW stock.
Based on Q4 2025 13F filings, institutional ownership of BriaCell Therapeutics Corp. stands at 200.0%, held across 7 reporting institutions.
SUSQUEHANNA INTERNATIONAL GROUP, LLP is the largest reported institutional holder of BCTXW, with approximately 67,111 shares worth $0.00B as of Q4 2025.
Yes β 1 widely-followed marquee investor appear among the top 25 institutional holders of BCTXW, including SUSQUEHANNA INTERNATIONAL GROUP, LLP.
Our composite Smart Money Score for BCTXW is 59 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
5 institutions opened new positions in BCTXW during Q4 2025, while 1 fully exited. 1 added to existing positions and 1 trimmed.
BCTXW institutional ownership rose by 0.00 percentage points quarter-over-quarter, with a net change of +4 holders.
The top 10 institutions account for 100.0% of all reported 13F value in BCTXW, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
BriaCell Therapeutics Corp. (BCTXW) Institutional Ownership